Final hours! Save up to 55% OFF InvestingProCLAIM SALE

J&J may eye deals that boost eye care, surgical robots businesses - CEO

Published 01/09/2023, 02:35 PM
Updated 01/09/2023, 04:32 PM
© Reuters. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo
JNJ
-
ABMD
-

By Leroy Leo and Aditya Samal

(Reuters) - Johnson & Johnson (NYSE:JNJ) will look for opportunities to merge with or acquire firms that add value to its focus areas of eye care, surgical robots, orthopedics and cardiovascular products, the company's Chief Executive Officer Joaquin Duato said on Monday.

The healthcare giant is in the process of spinning off its consumer healthcare business under the brand Kenvue to focus on its pharmaceutical and medical devices businesses.

"We'll continue to be disciplined in looking for opportunities in which we can create value that serve a significant unmet medical need like heart failure," Duato said at the J.P. Morgan Healthcare Conference.

J&J last month completed its acquisition of heart pump maker Abiomed (NASDAQ:ABMD) for $16.6 billion, which will operate as an independent division in its medical devices business.

© Reuters. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo

Duato said many of its future deals would likely be small "tuck-in" acquisitions.

The company's CEO expects J&J to continue growing towards its goal of $60 billion in pharmaceutical sales by 2025, and is confident of exceeding current Street expectations by the targeted year.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.